Scientists identify molecular therapy to prevent growth of pediatric leukemia
Northwestern Medicine scientists have discovered the genetic driver of a rare and lethal childhood leukemia and identified a targeted molecular therapy that halts the proliferation of leukemic cells. The finding also has implications for treating other types of cancer.
Mixed lineage leukemia (MLL) primarily strikes newborns and infants. Less than 10 to 20 percent of those children (300 cases are seen in the United States per year) live no more than five years after being diagnosed.
“We’ve spent the last 20 years in my laboratory trying to molecularly understand how MLL translocations cause this rare and devastating form of leukemia in children so that we can use this information to develop an effective therapy for this cancer,” said lead investigator Ali Shilatifard, PhD, Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics. “Now we’ve made a fundamentally important breakthrough.”
The paper was published Jan. 5 in the journal Cell.
Shilatifard, his graduate student Kevin Liang and their colleagues at Feinberg are extremely hopeful about this breakthrough and are in the process of pushing their findings into clinic for the treatment of childhood leukemia.
“Mixed lineage leukemia is caused when an errant chromosome 11 on the MLL gene breaks and attaches to other chromosomes such as chromosome 19, where it doesn’t belong,” said Liang, the paper’s first author. “The mutation produces a protein that drives the pathogenesis of leukemia.”
[pullquote]“We’ve spent the last 20 years … trying to molecularly understand how MLL translocations cause this rare and devastating form of leukemia in children so that we can use this information to develop an effective therapy for this cancer.”[/pullquote]
Most research related to this cancer has focused on the errant version of chromosome 11. But there are two copies of chromosome 11, and the Shilatifard group wanted to investigate the wild-type version. Shilatifard’s laboratory discovered that individual cells with the pediatric leukemia had extremely low levels of a protein produced by the wild-type MLL gene. Shilatifard and Liang reasoned if they could beef up the levels of the wild-type MLL protein, it would displace the mutated version that drives cancer, and it could cure leukemia.
Through their detailed molecular and biochemical screens, Shilatifard’s lab identified a compound that stabilized the wild-type MLL and interfered with the mutant protein driving leukemia. To test its effectiveness, they grew mixed lineage leukemia cells in a culture and transplanted them into mice, in collaboration with the lab of John Crispino, PhD, Robert I. Lurie, MD, and Lora S. Lurie Professor of Medicine in the Division of Hematology/Oncology, and his fellow Andrew Volk. They then injected the therapeutic compound into the mice. The result: the wild-type MLL bounced back to healthy levels, and the leukemic cells were not able to grow as rapidly.
Northwestern scientists are now synthesizing better compounds and hope to eventually launch a Phase I trial to test these compounds in Chicago.
Shilatifard is also a professor of Pediatrics and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Other Northwestern authors in the manuscript include Stacy Marshall, Ashley Woodfin, Elizabeth Bartom, PhD, and Edwin Smith, PhD. The study was also done in collaboration with colleagues at Stowers Institute, where Shilatifard’s laboratory used to be prior to his joining Northwestern Medicine in 2014.
Shilatifard’s laboratory is supported by the Outstanding Investigator Award from the National Cancer Institute grant R35CA197569 of the National Institutes of Health.
